Spots Global Cancer Trial Database for reduced intensity conditioning
Every month we try and update this database with for reduced intensity conditioning cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Allogeneic Hematopoietic Stem Cell Transplantation | NCT00750126 | Solid Tumors Hematologic Neo... | Fludarabine, Bu... | - 20 Years | University Hospital, Clermont-Ferrand | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | NCT02098512 | Hodgkin Lymphom... | Brentuximab Ved... Allogeneic Stem... Reduced Intensi... | - 45 Years | New York Medical College | |
| Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) | NCT00607854 | Diffuse Large B... Mantle Cell Lym... | Ibritumomab Tiu... | 18 Years - 65 Years | University Hospital, Bordeaux | |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | NCT03159702 | Hematological M... Multiple Myelom... | Evomela Fludarabine Total Body Irra... | 18 Years - | Medical College of Wisconsin | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant | NCT00143845 | Multiple Myelom... Lymphocytic Leu... Lymphoma, Low-G... | Reduced intensi... Rapid immunosup... Prophylactic do... | - | University of Michigan Rogel Cancer Center | |
| Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning | NCT00466674 | Myeloma | reduced intensi... | 18 Years - 65 Years | Hospices Civils de Lyon | |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning | NCT03852407 | Acute Myeloid L... Myelodysplastic... Chronic Myeloid... Myeloproliferat... Myeloproliferat... Acute Lymphoid ... Multiple Myelom... Chronic Lymphoi... Non Hodgkin Lym... Hodgkin Lymphom... | Thymoglobulin Melphalan Fludarabine Cyclophosphamid | 18 Years - 75 Years | University of Liege | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| A Phase II Study of Umbilical Cord Blood Transplantation | NCT00676806 | Leukemia Lymphoma Multiple Myelom... Aplastic Anemia | Umbilical Cord ... Umbilical Cord ... | - 70 Years | Tufts Medical Center | |
| A Phase II Study of Umbilical Cord Blood Transplantation | NCT00676806 | Leukemia Lymphoma Multiple Myelom... Aplastic Anemia | Umbilical Cord ... Umbilical Cord ... | - 70 Years | Tufts Medical Center | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML | NCT06267898 | MDS CMML | 18 Years - | European Society for Blood and Marrow Transplantation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
